These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26651453)

  • 41. Metabolic syndrome impairs physical function, health-related quality of life, and peripheral circulation in patients with intermittent claudication.
    Gardner AW; Montgomery PS; Parker DE
    J Vasc Surg; 2006 Jun; 43(6):1191-6; discussion 1197. PubMed ID: 16765237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adaptation of external counterpulsation based on individual shear rate therapy improves endothelial function and claudication distance in peripheral artery disease.
    Buschmann EE; Brix M; Li L; Doreen J; Zietzer A; Li M; Buschmann I; Hillmeister P
    Vasa; 2016; 45(4):317-24. PubMed ID: 27428501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication.
    Diehm C; Pittrow D; Lawall H
    J Hypertens; 2011 Jul; 29(7):1448-56. PubMed ID: 21602713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
    Messa GL; Gelso E
    Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
    Rajagopalan S; Olin JW; Young S; Erikson M; Grossman PM; Mendelsohn FO; Regensteiner JG; Hiatt WR; Annex BH
    Hum Gene Ther; 2004 Jun; 15(6):619-24. PubMed ID: 15212720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute impairment of the endothelial function by maximal treadmill exercise in patients with intermittent claudication, and its improvement after supervised physical training.
    Andreozzi GM; Leone A; Laudani R; Deinite G; Martini R
    Int Angiol; 2007 Mar; 26(1):12-7. PubMed ID: 17353883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized controlled trial using bosentan to enhance the impact of exercise training in subjects with type 2 diabetes mellitus.
    Schreuder TH; Duncker DJ; Hopman MT; Thijssen DH
    Exp Physiol; 2014 Nov; 99(11):1538-47. PubMed ID: 25172889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.
    Subramaniyam V; Waller EK; Murrow JR; Manatunga A; Lonial S; Kasirajan K; Sutcliffe D; Harris W; Taylor WR; Alexander RW; Quyyumi AA
    Am Heart J; 2009 Jul; 158(1):53-60.e1. PubMed ID: 19540392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment.
    Bagger JP; Helligsoe P; Randsbaek F; Kimose HH; Jensen BS
    Circulation; 1997 Jan; 95(2):411-4. PubMed ID: 9008458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.
    Mohler ER; Gainer JL; Whitten K; Eraso LH; Thanaporn PK; Bauer T
    Vasc Med; 2011 Oct; 16(5):346-53. PubMed ID: 22003000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Onset of peripheral arterial disease: role of endothelin in endothelial dysfunction.
    de Haro Miralles J; Gónzalez AF; Varela Casariego C; García FA
    Interact Cardiovasc Thorac Surg; 2010 May; 10(5):760-5. PubMed ID: 20154344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bosentan preserves endothelial function in mice overexpressing APP.
    Elesber AA; Bonetti PO; Woodrum JE; Zhu XY; Lerman LO; Younkin SG; Lerman A
    Neurobiol Aging; 2006 Mar; 27(3):446-50. PubMed ID: 15894408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial.
    Lazarous DF; Unger EF; Epstein SE; Stine A; Arevalo JL; Chew EY; Quyyumi AA
    J Am Coll Cardiol; 2000 Oct; 36(4):1239-44. PubMed ID: 11028477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preprogrammed oscillations improve lower limb blood flow and walking distance in patients with peripheral arterial disease.
    Rabin I; Shpolanski U; Leibovitz A; Bass A
    Isr Med Assoc J; 2014 Jul; 16(7):423-6. PubMed ID: 25167687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.
    Flórez A; de Haro J; Martínez E; Varela C; Bleda S; Acín F
    Rev Esp Cardiol; 2009 Aug; 62(8):851-7. PubMed ID: 19706240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
    Hiatt WR; Hirsch AT; Cooke JP; Olin JW; Brater DC; Creager MA
    Vasc Med; 2004 Feb; 9(1):18-25. PubMed ID: 15230484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
    Lewis RJ; Connor JT; Teerlink JR; Murphy JR; Cooper LT; Hiatt WR; Brass EP
    Trials; 2011 May; 12():134. PubMed ID: 21612611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: a randomized controlled trial.
    De Maria R; Campolo J; Frontali M; Taroni F; Federico A; Inzitari D; Tavani A; Romano S; Puca E; Orzi F; Francia A; Mariotti C; Tomasello C; Dotti MT; Stromillo ML; Pantoni L; Pescini F; Valenti R; Pelucchi C; Parolini M; Parodi O;
    Stroke; 2014 Oct; 45(10):2959-66. PubMed ID: 25184356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.